Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

Iris-Katharina Penner, Brigitte Stemper, Pasquale Calabrese, Mark S Freedman, Chris H Polman, Gilles Edan, Hans-Peter Hartung, David H Miller, Xavier Montalbán, Frederik Barkhof, Dirk Pleimes, Vivian Lanius, Christoph Pohl, Ludwig Kappos, Rupert Sandbrink, Iris-Katharina Penner, Brigitte Stemper, Pasquale Calabrese, Mark S Freedman, Chris H Polman, Gilles Edan, Hans-Peter Hartung, David H Miller, Xavier Montalbán, Frederik Barkhof, Dirk Pleimes, Vivian Lanius, Christoph Pohl, Ludwig Kappos, Rupert Sandbrink

Abstract

Background: Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS).

Methods: We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition was assessed by Paced Auditory Serial Addition Test-3" (PASAT-3") scores.

Results: Improvement in PASAT-3" score from baseline to year two was greater for IFNβ-1b treatment than placebo in patients not reaching clinically definite MS (CDMS) by year two. The treatment effect was maintained at year five and was statistically significant.

Conclusions: To conclude, early IFNβ-1b treatment had a sustained positive effect on PASAT-3" score over the 5-year BENEFIT study.

Figures

Figure 1.
Figure 1.
Relationship between treatment, PASAT-3” baseline performance and PASAT 3” improvement over 5 years. PASAT-3”:Paced Auditory Serial Addition Test-3”

References

    1. Patti F. Cognitive impairment in multiple sclerosis. Mult Scler 2009; 15: 2–8
    1. Potagas C, Giogkaraki E, Koutsis G, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci 2008; 267: 100–106
    1. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatr 2003; 74: 443–446
    1. Feuillet L, Reuter F, Audoin B, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007; 13: 124–127
    1. Glanz BI, Holland CM, Gauthier SA, et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007; 13: 1004–1010
    1. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503–1511
    1. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904
    1. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987–997
    1. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249
    1. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–1582
    1. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489–1496
    1. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48: 885–892
    1. Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56: 319–324
    1. Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007; 255: 57–63
    1. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871–882
    1. Bever CT, Jr, Grattan L, Panitch HS, et al. The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult Scler 1995; 1: 165–169
    1. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006; 12: 549–558
    1. Amato MP, Ponziani G, Pracucci G, et al. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995; 52: 168–172
    1. Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II Impact on employment and social functioning. Neurology 1991; 41: 692–696

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj